CXCL5 and cancer: To test this, we added exogenous recombinant CXCL5 protein (rCXCL5) to healthy bone cultures or SB225002, an inhibitor of CXCR261, to our highly proliferative IC bone cultures and quantified the percentage of Ki67+Keratin+ cancer cells (Fig. 3d).